| Name | Cvs Pharmacy #05431 |
|---|---|
| Organization Name | Ohio Cvs Stores Llc |
| Location | 592 West Plane Street, Bethel, Ohio 45106 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (513) 734-6242 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Amgen today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program.
A new study has shown that some nasty bacteria can survive and grow for at least 24 hours on computer keyboards and electronic recordkeeping in hospitals and other health care settings and may be spreading more than just information.
Curis, a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has selected CUDC-907, an orally available, synthetic small molecule inhibitor of phosphatidylinositol-3-kinase and histone deacetylase as a development candidate from its targeted cancer programs.
Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatment which can be harmful to the developing brain. The most common childhood brain tumors are medulloblastoma and pylocytic astrocytoma.
› Verified 5 days ago
| NPI Number | 1982708715 |
| Organization Name | OHIO CVS STORES LLC |
| Doing Business As | CVS PHARMACY 05431 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 592 W Plane St, Bethel, OH 45106 |
| Phone Number | 513-734-6243 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Amgen today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program.
A new study has shown that some nasty bacteria can survive and grow for at least 24 hours on computer keyboards and electronic recordkeeping in hospitals and other health care settings and may be spreading more than just information.
Curis, a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has selected CUDC-907, an orally available, synthetic small molecule inhibitor of phosphatidylinositol-3-kinase and histone deacetylase as a development candidate from its targeted cancer programs.
Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatment which can be harmful to the developing brain. The most common childhood brain tumors are medulloblastoma and pylocytic astrocytoma.
› Verified 5 days ago
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Amgen today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program.
A new study has shown that some nasty bacteria can survive and grow for at least 24 hours on computer keyboards and electronic recordkeeping in hospitals and other health care settings and may be spreading more than just information.
Curis, a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has selected CUDC-907, an orally available, synthetic small molecule inhibitor of phosphatidylinositol-3-kinase and histone deacetylase as a development candidate from its targeted cancer programs.
Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatment which can be harmful to the developing brain. The most common childhood brain tumors are medulloblastoma and pylocytic astrocytoma.
› Verified 5 days ago
Cvs Pharmacy #05431 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 592 West Plane Street, Bethel, Ohio 45106 Phone: (513) 734-6242 | |
Fitzgerald Bethel Pharmacy Inc Type: Community/Retail Pharmacy Location: 697 W Plane St, Bethel, Ohio 45106 Phone: (513) 734-3784 |